ObsEva files uterine fibroid drug in US, chasing AbbVie, Myovant
pharmaphorum
SEPTEMBER 15, 2021
If approved, linzagolix will be the only drug in the class with a dosing regimen intended for women with uterine fibroids who cannot or do not want to take hormone therapy, as well as options for those women happy to do so, according to ObsEva.
Let's personalize your content